FDA approves Dova’s Doptelet for thrombocytopenia in adults with CLD
The approval for the thrombopoietin (TPO) receptor agonist is for adult patients who are scheduled to go through a medical or dental procedure. The regulator said Doptelet is the
Novartis has signed an agreement to acquire biotech business Excellergy, which specialises in the development of next-generation anti-immunoglobulin e (IgE) therapies for up to $2bn in upfront and milestone payments.